Coronavirus | Israel signs deal with Pfizer for potential COVID-19 vaccine

‘Israel will receive 8 million doses of the vaccine’

November 13, 2020 05:45 pm | Updated 05:45 pm IST - TEL AVIV

Pfizer on Monday announced that its experimental COVID-19 vaccine was more than 90% effective based on initial trial results

Pfizer on Monday announced that its experimental COVID-19 vaccine was more than 90% effective based on initial trial results

Israel signed a deal with Pfizer Inc on Friday to receive 8 million doses of the drugmaker's potential COVID-19 vaccine, Prime Minister Benjamin Netanyahu said, enough to cover close to half of Israel's population.

Pfizer and German partner BioNTech SE confirmed a deal was forthcoming in a statement on Thursday but did not disclose financial details. There was no immediate comment from the two companies on Friday.

The agreement still requires approval by the U.S. Food and Drug Administration (FDA) and Israel's Health Ministry, Israeli Health Minister Yuli Edelstein said. Pfizer is expected to apply for approval this month, he added.

Pfizer's potential vaccine is likely to be a two-dose course of treatment, meaning that 8 million doses would cover 4 million of Israel's 9 million population.

In televised remarks, Mr. Netanyahu said the agreement marked “a great day for Israel” and added: “The goal is for the vaccine supply to start in January and increase in the months thereafter”.

Pfizer on Monday announced that its experimental COVID-19 vaccine was more than 90% effective based on initial trial results, a potential major victory in the war against a virus that has killed more than a million people and battered the world economy.

In addition to its new deal with Pfizer, Israel has an agreement with Moderna Inc for the future purchase of its potential vaccine. Moderna said on Wednesday it had enough data for a first interim analysis of the late-stage trial of its vaccine candidate.

Top News Today

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.